Return to Trial Database

HCRN-BRE20-468

A Phase II Study of Ribociclib And Endocrine Treatment of Physician’s Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)

Status

Currently Enrolling

Cancer Type(s)

Study Contact

studies@hoosiercancer.org

Trial Locations

All sites in which the trial HCRN-BRE20-468 being conducted in.

Fred & Pamela Buffett Cancer Center

New York University Cancer Institute

Orlando Health Cancer Institute

Parkview Research Center

Penn State Cancer Institute

Providence Cancer Institute

Rutgers Cancer Institute of New Jersey

The Ohio State University

Tufts Medical Center

University of Alabama at Birmingham Comprehensive Cancer Center

University of Arizona Cancer Center

University of Illinois Cancer Center

University of Iowa Holden Comprehensive Cancer Center

University of Michigan Health-West

University of Michigan Rogel Cancer Center

University of Virginia Cancer Center

University of Wisconsin Carbone Cancer Center

Virginia Commonwealth University